Important Clarification on HIMS' Recent News 👇🏻

$HIMS (-1.68%) As you may read here, the FDA has confirmed that semaglutide remains in shortage.

This means $HIMS can continue selling its compounded GLP-1s, as the company exclusively offers semaglutide, not tirzepatide.